Management of patients with HER2-positive metastatic breast ...
Risk factors for CHF: low LVEF, age, obesity, hypertension. ? LVEF is mandatory before initiation of trastuzumab and during treatment. ESO-ESMO EEBR Masterclass ...
Real-world treatment patterns and outcomes of patients with HER2+ ...Eligible studies were randomised controlled trials (RCTs) that compared a treatment duration of 6 months or less (?6 months) of trastuzumab or ... MANAGEMENT OF HER2-POSITIVE BREAST CANCERThis study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with. HER2-TARGETED THERAPIES IN BREAST CANCERBackground: Trastuzumab deruxtecan (T-DXd) currently represents the standard of care for the treatment of patients with metastatic HER2-positive. (HER2+) breast ...
Autres Cours:
